Correlation between anti-Mullerian hormone levels and antral follicle counts in polycystic ovary and metabolic syndromes

Fu, Henry; You-shi, Lin; Deng, Xueqing; Wu, Lian

doi:10.1080/19396368.2020.1860155

Cited by 7 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been hypothesised that low levels of AMH serve as a signal for an increased likelihood of developing metabolic syndrome. There was not a significant difference in the mean fasting insulin levels between obese and non-obesity subjects in the groups with elevated AMH levels (P = 0.12 and P = 0.75), according to our findings [14].…”

Section: Discussionsupporting

confidence: 64%

Normoglycemic Obese and Non-Obese Women From North India With Polycystic Ovary Syndrome And Anti-Mullerian Hormone

Dr. Ramkumar Boopathirajan,

Dr. R. Hemakairavi,

Dr. Mohamed Jainul Azarudeen

2023

IARJMSR

View full text Add to dashboard Cite

Objective: Anti-Mullerian Hormone, often known as AMH, has been linked to a number of pathological disorders affecting the ovary, one of which is polycystic ovarian syndrome (PCOS). These patients' obesity, BMI, and hyperandrogenism are the triggers for a rise in the number of tiny antral follicles, which in turn affects the amount of AMH secreted. Method: AMH levels were compared with clinical, biochemical, and hormonal profiles in obese and non-obese PCOS women from Department of Community Medicine, TRR Institute of Medical Sciences, TRR Nagar, Inole, Hyderabad, Telangana, India, for the purpose of this study. Results: For this investigation, 54 cases of normoglycemic PCOS women were included. Among the patients, 62 (57.4%) had a BMI under 25 kg/m2, while 46 (42.6%) were obese. 48 patients (44.4%) had AMH 10 ng/ml. AMH 5ng/ml and obese PCOS individuals had significantly increased mean fasting insulin (P=0.01). In non-obese PCOS patients with AMH levels less than 5ng/ml, mean serum LDL-c was considerably higher (P=0.01), and mean serum LH was significantly higher in non-obese individuals with AMH 10ng/ml. Conclusion: Low AMH can be a significant marker for PCOS, and it should be routinely evaluated both for the diagnosis of PCOS and for the management of patients who have the condition. This is true regardless of the patient's BMI.

show abstract

Section: Discussionsupporting

confidence: 64%

Normoglycemic Obese and Non-Obese Women From North India With Polycystic Ovary Syndrome And Anti-Mullerian Hormone

Dr. Ramkumar Boopathirajan,

Dr. R. Hemakairavi,

Dr. Mohamed Jainul Azarudeen

2023

IARJMSR

View full text Add to dashboard Cite

show abstract

“…Previous studies considered LDL as the standard of PCOS metabolic syndrome, and lipid metabolism disorder is an important influencing factor of PCOS [ 24 ]. Hyperandrogenemia, insulin resistance, obesity, and dyslipidemia are all potential influencing factors contributing to PCOS metabolic syndrome and are the results of interaction; However, the precise mechanisms of interaction remain unclear [ 25 ]. Therefore, assessing the glucose metabolism and hormonal and lipid profiles of patients with PCOS is essential, and, when necessary, interventions should be aimed at mitigating risk factors associated with PCOS progression [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

Assessing the clinical diagnostic value of anti-Müllerian hormone in polycystic ovarian syndrome and its correlation with clinical and metabolism indicators

Wang,

Luo,

et al. 2024

J Ovarian Res

View full text Add to dashboard Cite

Background This study investigated the association between Anti-Müllerian Hormone (AMH) and relevant metabolic parameters and assessed its predictive value in the clinical diagnosis of polycystic ovarian syndrome (PCOS). Methods A total of 421 women aged 20–37 years were allocated to the PCOS (n = 168) and control (n = 253) groups, and their metabolic and hormonal parameters were compared. Spearman correlation analysis was conducted to investigate associations, binary logistic regression was used to determine PCOS risk factors, and receiver operating characteristic (ROC) curves were generated to evaluate the predictive value of AMH in diagnosing PCOS. Results The PCOS group demonstrated significantly higher blood lipid, luteinizing hormone (LH), and AMH levels than the control group. Glucose and lipid metabolism and hormonal disorders in the PCOS group were more significant than in the control group among individuals with and without obesity. LH, TSTO, and AMH were identified as independent risk factors for PCOS. AMH along with LH, and antral follicle count demonstrated a high predictive value for diagnosing PCOS. Conclusion AMH exhibited robust diagnostic use for identifying PCOS and could be considered a marker for screening PCOS to improve PCOS diagnostic accuracy. Attention should be paid to the effect of glucose and lipid metabolism on the hormonal and related parameters of PCOS populations.

show abstract

“…A dysfunction in the immune system affects follicular development or ovulation [ 31 ]. On the other hand, an increase in inflammatory factors in PCOS patients changes the level of AMH, resulting in glucose and lipid metabolism disorder [ 32 , 33 ]. This disorder increases the risk of IR and synthesis of androgens, destroying normal ovulation and fertilization in women.…”

Section: Discussionmentioning

confidence: 99%

Short-chain fatty acid-butyric acid ameliorates granulosa cells inflammation through regulating METTL3-mediated N6-methyladenosine modification of FOSL2 in polycystic ovarian syndrome

Liu

Huang

et al. 2023

Clin Epigenet

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is an endocrine and metabolic disorder characterized by chronic low-grade inflammation. Previous studies have demonstrated that the gut microbiome can affect the host tissue cells’ mRNA N6-methyladenosine (m6A) modifications. This study aimed to understand the role of intestinal flora in ovarian cells inflammation by regulating mRNA m6A modification particularly the inflammatory state in PCOS. The gut microbiome composition of PCOS and Control groups was analyzed by 16S rRNA sequencing, and the short chain fatty acids were detected in patients’ serum by mass spectrometry methods. The level of butyric acid was found to be decreased in the serum of the obese PCOS group (FAT) compared to other groups, and this was correlated with increased Streptococcaceae and decreased Rikenellaceae based on the Spearman’s rank test. Additionally, we identified FOSL2 as a potential METTL3 target using RNA-seq and MeRIP-seq methodologies. Cellular experiments demonstrated that the addition of butyric acid led to a decrease in FOSL2 m6A methylation levels and mRNA expression by suppressing the expression of METTL3, an m6A methyltransferase. Additionally, NLRP3 protein expression and the expression of inflammatory cytokines (IL-6 and TNF-α) were downregulated in KGN cells. Butyric acid supplementation in obese PCOS mice improved ovarian function and decreased the expression of local inflammatory factors in the ovary. Taken together, the correlation between the gut microbiome and PCOS may unveil crucial mechanisms for the role of specific gut microbiota in the pathogenesis of PCOS. Furthermore, butyric acid may present new prospects for future PCOS treatments.

show abstract

Correlation between anti-Mullerian hormone levels and antral follicle counts in polycystic ovary and metabolic syndromes

Cited by 7 publications

References 30 publications

Normoglycemic Obese and Non-Obese Women From North India With Polycystic Ovary Syndrome And Anti-Mullerian Hormone

Normoglycemic Obese and Non-Obese Women From North India With Polycystic Ovary Syndrome And Anti-Mullerian Hormone

Assessing the clinical diagnostic value of anti-Müllerian hormone in polycystic ovarian syndrome and its correlation with clinical and metabolism indicators

Short-chain fatty acid-butyric acid ameliorates granulosa cells inflammation through regulating METTL3-mediated N6-methyladenosine modification of FOSL2 in polycystic ovarian syndrome

Contact Info

Product

Resources

About